PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32495214-0 2020 The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells. Maytansine 65-74 immunoglobulin heavy diversity 1-7 Homo sapiens 78-81 32495214-1 2020 Trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) of trastuzumab and cytotoxic agent emtansine (DM1), has been approved for the therapy of metastatic HER2-positive breast cancer after prior treatment of trastuzumab and taxane. Maytansine 12-21 immunoglobulin heavy diversity 1-7 Homo sapiens 25-28 32495214-1 2020 Trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) of trastuzumab and cytotoxic agent emtansine (DM1), has been approved for the therapy of metastatic HER2-positive breast cancer after prior treatment of trastuzumab and taxane. Maytansine 12-21 immunoglobulin heavy diversity 1-7 Homo sapiens 110-113 32495214-1 2020 Trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) of trastuzumab and cytotoxic agent emtansine (DM1), has been approved for the therapy of metastatic HER2-positive breast cancer after prior treatment of trastuzumab and taxane. Maytansine 99-108 immunoglobulin heavy diversity 1-7 Homo sapiens 25-28 28894364-1 2017 DM1, a maytansine derivative, is a highly potential cytotoxic agent but with severe side effects; therefore, its application in clinical cancer therapy is limited. Maytansine 7-17 immunoglobulin heavy diversity 1-7 Homo sapiens 0-3 31484985-1 2019 T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. Maytansine 67-76 immunoglobulin heavy diversity 1-7 Homo sapiens 2-5 31416167-2 2019 The therapeutic potential of using an affibody molecule targeting HER2, fused to an albumin-binding domain (ABD) and conjugated with the cytotoxic maytansine derivate MC-DM1 (AffiDC), has been validated. Maytansine 147-157 immunoglobulin heavy diversity 1-7 Homo sapiens 170-173 29214842-1 2018 Trastuzumab emtansine is an antibody-drug conjugate comprised of the anti-HER2 monoclonal antibody trastuzumab linked to DM1 (emtansine), a potent cytotoxic maytansinoid derivative, by a stable linker. Maytansine 12-21 immunoglobulin heavy diversity 1-7 Homo sapiens 121-124 28648785-5 2017 This approach led to the successful development of LC-MS validated bioanalysis of the antibody and released drugs within 20% for lower limit of quantitation and 15% for another concentration setting of Trastuzumab emtansine (T-DM1), Trastuzumab antibody and emtansine conjugated with crosslinker (DM1-MCC). Maytansine 214-223 immunoglobulin heavy diversity 1-7 Homo sapiens 227-230 28377489-4 2017 REGN2878-DM1 is comprised of a fully human high-affinity function-blocking anti-PRLR IgG1 antibody (REGN2878) conjugated via a noncleavable SMCC linker to the cytotoxic maytansine derivative DM1. Maytansine 169-179 immunoglobulin heavy diversity 1-7 Homo sapiens 9-12 28552047-5 2017 T-DM1 is a novel antibody-drug conjugate, combining trastuzumab with a potent cytotoxic, DM1, a maytansine derivative, via a stable thioether linker. Maytansine 96-106 immunoglobulin heavy diversity 1-7 Homo sapiens 2-5 28552047-5 2017 T-DM1 is a novel antibody-drug conjugate, combining trastuzumab with a potent cytotoxic, DM1, a maytansine derivative, via a stable thioether linker. Maytansine 96-106 immunoglobulin heavy diversity 1-7 Homo sapiens 89-92 27274311-3 2016 Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that results from the combination of trastuzumab and DM1, a derivative of the antimicrotubule agent maytansine. Maytansine 160-170 immunoglobulin heavy diversity 1-7 Homo sapiens 25-28 27274311-3 2016 Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that results from the combination of trastuzumab and DM1, a derivative of the antimicrotubule agent maytansine. Maytansine 160-170 immunoglobulin heavy diversity 1-7 Homo sapiens 113-116 26254411-1 2015 AIM: To compare results of trastuzumab-emtansine (T-DM1) treatment in our clinical practice with data from phase III clinical trials. Maytansine 39-48 immunoglobulin heavy diversity 1-7 Homo sapiens 52-55 26240273-3 2015 The fully human anti-RET antibody (Y078) was conjugated to the DM1 and DM4 derivatives of the potent cytotoxic agent maytansine using thioether and disulfide linkers, respectively. Maytansine 117-127 immunoglobulin heavy diversity 1-7 Homo sapiens 63-66 26938945-2 2016 In the case of trastuzumab-DM1 (T-DM1), approved for the treatment of metastatic breast cancer, the addition of mertansine (DM1) to trastuzumab substantially increased progression-free survival. Maytansine 112-122 immunoglobulin heavy diversity 1-7 Homo sapiens 27-30 26938945-2 2016 In the case of trastuzumab-DM1 (T-DM1), approved for the treatment of metastatic breast cancer, the addition of mertansine (DM1) to trastuzumab substantially increased progression-free survival. Maytansine 112-122 immunoglobulin heavy diversity 1-7 Homo sapiens 34-37 26938945-2 2016 In the case of trastuzumab-DM1 (T-DM1), approved for the treatment of metastatic breast cancer, the addition of mertansine (DM1) to trastuzumab substantially increased progression-free survival. Maytansine 112-122 immunoglobulin heavy diversity 1-7 Homo sapiens 34-37 25756468-2 2016 It is a human epidermal growth factor receptor (HER-2)-targeted antibody-drug conjugate composed of trastuzumab, a stable thioether linker, and the potent cytotoxic agent DM1 (derivative of maytansine). Maytansine 190-200 immunoglobulin heavy diversity 1-7 Homo sapiens 171-174 26318092-1 2016 BACKGROUND: Trastuzumab emtansine (T-DM1), a new agent developed for the treatment of HER2-positive breast cancer, is an antibody-drug conjugate with a complex compound obtained by the conjugation of trastuzumab, a stable thioether linker, and the potent cytotoxic drug maytansine-derivate(DM1), which inhibits cell division and induces cell death. Maytansine 24-33 immunoglobulin heavy diversity 1-7 Homo sapiens 37-40 26318092-1 2016 BACKGROUND: Trastuzumab emtansine (T-DM1), a new agent developed for the treatment of HER2-positive breast cancer, is an antibody-drug conjugate with a complex compound obtained by the conjugation of trastuzumab, a stable thioether linker, and the potent cytotoxic drug maytansine-derivate(DM1), which inhibits cell division and induces cell death. Maytansine 24-33 immunoglobulin heavy diversity 1-7 Homo sapiens 290-293 26318092-1 2016 BACKGROUND: Trastuzumab emtansine (T-DM1), a new agent developed for the treatment of HER2-positive breast cancer, is an antibody-drug conjugate with a complex compound obtained by the conjugation of trastuzumab, a stable thioether linker, and the potent cytotoxic drug maytansine-derivate(DM1), which inhibits cell division and induces cell death. Maytansine 270-280 immunoglobulin heavy diversity 1-7 Homo sapiens 37-40 25398397-2 2015 We evaluated the efficacy of trastuzumab-emtansine (T-DM1), against primary HER2 positive and HER2 negative CS cell lines in vitro and in vivo. Maytansine 41-50 immunoglobulin heavy diversity 1-7 Homo sapiens 54-57 25865453-1 2015 INTRODUCTION: Ado- trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate composed of trastuzumab, a stable linker (MCC), and the cytotoxic agent DM1 (derivative of maytansine; mertansine). Maytansine 226-236 immunoglobulin heavy diversity 1-7 Homo sapiens 44-47 25865453-1 2015 INTRODUCTION: Ado- trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate composed of trastuzumab, a stable linker (MCC), and the cytotoxic agent DM1 (derivative of maytansine; mertansine). Maytansine 238-248 immunoglobulin heavy diversity 1-7 Homo sapiens 44-47 25790739-3 2015 Trastuzumab emtansine, consisting of trastuzumab coupled to a cytotoxic agent, emtansine (DM1), by a stable linker, has been approved in November 2013 by the European Medicine Agency. Maytansine 12-21 immunoglobulin heavy diversity 1-7 Homo sapiens 90-93 26031461-1 2015 DM1, a derivative of maytansine, is the cytotoxic component of the antibody-drug conjugate trastuzumab emtansine (T-DM1). Maytansine 21-31 immunoglobulin heavy diversity 1-7 Homo sapiens 0-3 26031461-1 2015 DM1, a derivative of maytansine, is the cytotoxic component of the antibody-drug conjugate trastuzumab emtansine (T-DM1). Maytansine 21-31 immunoglobulin heavy diversity 1-7 Homo sapiens 116-119 25339854-2 2014 In this research, emtansine (DM1)-loaded star-shaped folate-core polylactide-d-alpha-tocopheryl polyethylene glycol 1000 succinate (FA-PLA-TPGS-DM1) copolymer which demonstrated superior anticancer activity in vitro/vivo in comparison with linear FA-PLA-TPGS nanoparticles was applied to be a vector of DM1 for FR(+) breast cancer therapy. Maytansine 18-27 immunoglobulin heavy diversity 1-7 Homo sapiens 29-32 25191794-2 2014 DM1 is an analog of the natural product maytansine, a microtubule inhibitor that by itself has limited clinical activity and high systemic toxicity. Maytansine 40-50 immunoglobulin heavy diversity 1-7 Homo sapiens 0-3 25339854-2 2014 In this research, emtansine (DM1)-loaded star-shaped folate-core polylactide-d-alpha-tocopheryl polyethylene glycol 1000 succinate (FA-PLA-TPGS-DM1) copolymer which demonstrated superior anticancer activity in vitro/vivo in comparison with linear FA-PLA-TPGS nanoparticles was applied to be a vector of DM1 for FR(+) breast cancer therapy. Maytansine 18-27 immunoglobulin heavy diversity 1-7 Homo sapiens 144-147 25339854-2 2014 In this research, emtansine (DM1)-loaded star-shaped folate-core polylactide-d-alpha-tocopheryl polyethylene glycol 1000 succinate (FA-PLA-TPGS-DM1) copolymer which demonstrated superior anticancer activity in vitro/vivo in comparison with linear FA-PLA-TPGS nanoparticles was applied to be a vector of DM1 for FR(+) breast cancer therapy. Maytansine 18-27 immunoglobulin heavy diversity 1-7 Homo sapiens 144-147 24451727-6 2012 Trastuzumab emtansine (T-DM1) is a novel ADC that combines the humanized antibody trastuzumab and the potent antimicrotubule agent T-DM1 (derivative of maytansine) using a unique and highly stable linker. Maytansine 152-162 immunoglobulin heavy diversity 1-7 Homo sapiens 25-28 22942906-3 2012 Trastuzumab emtansine (T-DM1) is a novel antibody drug conjugate that consists of the HER2-targeted monoclonal antibody, trastuzumab, joined via a stable linker to a derivative of maytansine, a highly potent cytotoxic chemotherapy. Maytansine 180-190 immunoglobulin heavy diversity 1-7 Homo sapiens 25-28 23402224-1 2013 BACKGROUND: Trastuzumab emtansine (T-DM1), a novel drug developed for the treatment of HER2-positive breast cancer, is a human epidermal growth factor receptor (HER2) targeted antibody drug conjugate, composed of trastuzumab, a stable thioether linker, and the potent cytotoxic agent DM1 (derivative of maytansine). Maytansine 24-33 immunoglobulin heavy diversity 1-7 Homo sapiens 37-40 23402224-1 2013 BACKGROUND: Trastuzumab emtansine (T-DM1), a novel drug developed for the treatment of HER2-positive breast cancer, is a human epidermal growth factor receptor (HER2) targeted antibody drug conjugate, composed of trastuzumab, a stable thioether linker, and the potent cytotoxic agent DM1 (derivative of maytansine). Maytansine 24-33 immunoglobulin heavy diversity 1-7 Homo sapiens 284-287 23402224-1 2013 BACKGROUND: Trastuzumab emtansine (T-DM1), a novel drug developed for the treatment of HER2-positive breast cancer, is a human epidermal growth factor receptor (HER2) targeted antibody drug conjugate, composed of trastuzumab, a stable thioether linker, and the potent cytotoxic agent DM1 (derivative of maytansine). Maytansine 303-313 immunoglobulin heavy diversity 1-7 Homo sapiens 37-40 23247898-1 2012 Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) which associates the selective intracellular targeting of the cytotoxic agent, DM1 (maytansine derivative) to the antitumor activity of trastuzumab. Maytansine 150-160 immunoglobulin heavy diversity 1-7 Homo sapiens 25-28 23247898-1 2012 Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) which associates the selective intracellular targeting of the cytotoxic agent, DM1 (maytansine derivative) to the antitumor activity of trastuzumab. Maytansine 150-160 immunoglobulin heavy diversity 1-7 Homo sapiens 145-148 21481526-2 2011 DM1 is an antibody-conjugatable maytansinoid that was developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Maytansine 110-120 immunoglobulin heavy diversity 1-7 Homo sapiens 0-3 20730488-2 2011 Trastuzumab-DM1 (T-DM1, trastuzumab emtansine) is designed to combine the clinical benefits of trastuzumab with a potent microtubule-disrupting drug, DM1 (a maytansine derivative). Maytansine 157-167 immunoglobulin heavy diversity 1-7 Homo sapiens 12-15 21506905-1 2011 INTRODUCTION: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) that combines intracellular delivery of the potent cytotoxic agent, DM1 (a derivative of maytansine) with the antitumor activity of trastuzumab. Maytansine 169-179 immunoglobulin heavy diversity 1-7 Homo sapiens 39-42 21506905-1 2011 INTRODUCTION: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) that combines intracellular delivery of the potent cytotoxic agent, DM1 (a derivative of maytansine) with the antitumor activity of trastuzumab. Maytansine 169-179 immunoglobulin heavy diversity 1-7 Homo sapiens 148-151 21391620-6 2011 We found that the uncleavable mAb-SMCC-[(3)H]DM1 conjugate was degraded to a single major maytansinoid metabolite, lysine-SMCC-[(3)H]DM1, that was nearly 50-fold less cytotoxic than maytansine. Maytansine 182-192 immunoglobulin heavy diversity 1-7 Homo sapiens 45-48 21391620-6 2011 We found that the uncleavable mAb-SMCC-[(3)H]DM1 conjugate was degraded to a single major maytansinoid metabolite, lysine-SMCC-[(3)H]DM1, that was nearly 50-fold less cytotoxic than maytansine. Maytansine 182-192 immunoglobulin heavy diversity 1-7 Homo sapiens 133-136